|
|
| |
| 30% of Brains With Alzheimer’s Damage Never Show Symptoms. Now We May Know Why. |
| Some brains fight back. About three in ten older adults who develop the sticky amyloid plaques tied to Alzheimer’s never lose their memory. They think clearly. They remember names, faces, directions. Scientists have spent years trying to figure out what makes those brains different. |
| A team at the Netherlands Institute for Neuroscience, led by Evgenia Salta, may have found a clue. They studied donated brain tissue from three groups: healthy brains, brains from people who had Alzheimer’s dementia, and brains that showed Alzheimer’s damage but belonged to people who never lost their thinking ability. That last group is what researchers call “cognitively resilient.” |
| Let me explain what they found. Deep inside the brain’s memory center, there are rare, immature nerve cells — neurons that haven’t fully grown up. Salta’s team found these cells in all three groups, even in people over 80. But in the resilient group, those immature neurons behaved differently. They switched on survival programs. They showed less inflammation. Less cell death. |
| Think of them less like replacement parts and more like fertilizer in a garden that’s starting to fall apart. They don’t replace the dead plants. They keep the soil alive so the remaining plants can still grow. |
| |
The surprise: Resilient brains didn’t have dramatically more of these cells. The difference was in how the cells responded to damage — not in how many there were. |
|
| I could be wrong, of course. This is tissue analysis, not a controlled experiment. Salta herself says this is one piece of a large puzzle. But the direction is exciting. Instead of only asking why brains break down, scientists are now asking why some brains resist — and that’s a very different question with very different answers. |
| I urge you to pay attention to this line of work. If we can learn what keeps those immature neurons fighting, it could change how we think about prevention entirely. |
| Netherlands Institute for Neuroscience · April 24, 2026 |
|
|
|
|
| |
| The Sleep Efficiency Fix |
| Most people track how long they sleep. But a new study says the better number to watch is how well you sleep — what researchers call sleep efficiency. That’s the percentage of time in bed that you’re actually asleep, not lying there staring at the ceiling. |
| Prenuvo and sleep scientists at the University of Texas at Dallas scanned 14,031 adults with whole-body MRI. They found that people with higher sleep efficiency had more gray matter in the parietal lobe — the region that handles spatial thinking and attention. They also carried less visceral fat, the deep belly fat tied to inflammation and insulin resistance. |
| And one more thing that caught my eye: sleeping longer than eight hours was tied to a smaller hippocampus — your brain’s memory hub. So more isn’t always better. Efficient sleep is. |
| The Protocol |
| When |
| Every night, starting tonight. Set a fixed bedtime and a fixed wake time — same on weekends. |
| Duration |
| Aim for 7 to 8 hours in bed. Not more. If you can’t fall asleep within 20 minutes, get up and sit in dim light until you feel drowsy, then return. |
| Rules |
| No screens in the last 30 minutes before bed. No caffeine after noon. Keep the room cool — 65–68°F. Don’t nap past 2 p.m. or longer than 20 minutes. Track your wake time with a clock, not your phone. |
| |
| After one week, check if you feel more rested at the same bedtime. If you’re falling asleep fast and waking without an alarm, your efficiency is climbing. I urge you to try it — even a small gain in sleep efficiency shows up in your brain. |
|
|
|
|
|
|
|
| Testosterone Does Not Appear to Fix Menopause Brain Fog |
| Social media is full of claims that testosterone clears up the mental cloudiness many women get during menopause. A new review from University College London looked at the existing trial data and found insufficient evidence to support those claims. The researchers say the results don’t prove testosterone has zero effect — but the evidence so far doesn’t back the hype. Worth knowing if someone you care about is weighing this option. |
| University College London · Reproduction and Fertility · October 30, 2026 |
|
|
| Exercise Plus Social Activity Adds 7 Extra Sharp Years |
| Researchers pooled data from four long-running aging studies and found that adults over 50 who combined regular exercise with social and mental activities could expect to live an average of 7.2 more years without cognitive problems — compared to those who did little of either. Exercise alone added years. Social engagement alone added years. But the combination was far stronger than either on its own. Think of it as stacking two shields instead of carrying one. |
| Alzheimer’s & Dementia · October 1, 2026 |
|
|
| Air Pollution Shrinks the Brain Over Time, Scans Show |
| A new study in Environmental Pollution used repeated brain scans to track the same people over years. Those exposed to higher levels of fine particle pollution — the invisible soot from traffic and industry — showed measurable reductions in brain volume over time. This isn’t just a snapshot. It’s a time-lapse. And it adds to growing evidence that the air you breathe shapes the brain you keep. |
| Environmental Pollution · October 2026 |
|
|
|
|
| |
| Two things in development and one approved drug — a cortisol-blocking pill about to report results, a gene therapy aimed at tau, and five-year follow-up data on the most widely used Alzheimer’s antibody. |
|
| Lowers Cortisol in the Brain to Slow Memory Loss |
| Actinogen Medical’s oral drug Xanamem blocks an enzyme that produces cortisol — the stress hormone — inside the brain. Too much cortisol over time damages the hippocampus, where memories are formed. Their XanaMIA trial enrolled 247 people with mild to moderate Alzheimer’s and elevated tau markers. The database is now locked. Results are expected mid-November. If it works, this would be the first approved drug that targets cortisol’s role in Alzheimer’s directly. |
| Phase 2b/3 · Results expected mid-November 2026 |
|
|
| Uses Gene Therapy to Shut Down Tau Production |
| Voyager Therapeutics is developing VY1706, a one-time gene therapy designed to silence the gene that makes tau — the tangled protein that spreads through the brain in Alzheimer’s. Rather than clearing tau after it forms, this approach tries to stop the brain from making it in the first place. Voyager will present early data at the Clinical Trials on Alzheimer’s Disease conference in Boston on November 16–19. |
| Preclinical / Early Clinical · Data at CTAD November 2026 |
|
|
| Five Years of Data on the Most-Used Alzheimer’s Antibody |
| Eisai will present five-year follow-up data on lecanemab — sold as Leqembi — at the same Boston conference. Lecanemab is an intravenous antibody that clears amyloid plaques from the brain. The original trial showed a 27% slowing of decline over 18 months. Now we’ll see whether that benefit holds, grows, or fades over five years. That’s the question that matters most for anyone considering this treatment. |
| Marketed (approved) · 5-year data at CTAD November 16–19, 2026 |
|
|
